Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2019-12-19 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is titled 'Company Announcement' and details a strategic partnership, financial terms (upfront payment, equity investment, milestones), and collaboration scope between two companies (Genmab and CureVac). This type of announcement, which details a significant business development, partnership, or material event that is not a standard periodic financial report (like 10-K or IR), typically falls under general regulatory announcements or corporate news. Since it is a specific announcement of a material event (a strategic partnership) and not a standard financial filing, it is best classified as a Regulatory Filing (RNS) as it serves as a general regulatory disclosure of a significant event, or potentially a Capital/Financing Update (CAP) due to the equity investment and payment structure, but RNS is the broader, safer category for non-standard material corporate news releases. Given the context of a 'Company Announcement' detailing a major business deal, RNS is the most appropriate general regulatory disclosure category.
2019-12-19 English
Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
M&A Activity Classification · 99% confidence The document is titled "Company Announcement" and details a strategic partnership, financial terms (upfront payment, equity investment, milestones), and includes forward-looking statements. It is a formal communication from the company (Genmab A/S) to the market regarding a significant business development (collaboration/licensing agreement). This type of announcement, which is not a full financial report (10-K, IR), earnings release (ER), or a specific regulatory filing like insider trading (DIRS) or dividend notice (DIV), fits best under the general category of corporate news or regulatory filings. Since it announces a major business event and is structured as a press release, it is most appropriately classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) due to the equity investment, but RNS is the broader, safer category for non-standard announcements. Given the context of a major partnership announcement, RNS is the most suitable general classification.
2019-12-19 English
6-K
Foreign Filer Report
2019-12-17 English
6-K
Foreign Filer Report
2019-12-13 English
CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a corporate announcement from Genmab A/S regarding a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) for a drug (DARZALEX). It details the regulatory status of a product, clinical trial results (CASSIOPEIA study), and forward-looking statements. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement (RPA) as it provides the substantive news itself. Therefore, it is classified as a general regulatory announcement.
2019-12-13 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is titled 'Company Announcement' and details a positive opinion issued by the CHMP (Committee for Medicinal Products for Human Use) of the EMA regarding the marketing authorization for DARZALEX®. It includes key highlights, context about the clinical trial (CASSIOPEIA), and company background. This format—a brief, timely announcement of a significant regulatory/clinical event rather than a comprehensive financial report (like 10-K or IR) or a full transcript—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since this is a specific, material announcement about regulatory progress (a positive opinion leading to potential marketing authorization), it is best classified as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) as it is a formal communication of a regulatory milestone. Given the context of biotech/pharma announcements, these positive opinions are often released as immediate news updates, fitting the 'Earnings Release' style of communicating key operational/regulatory achievements, even if not strictly quarterly earnings. However, since it is a specific regulatory event announcement and not a financial results summary, 'RNS' (Regulatory Filings - general regulatory announcements) is the most appropriate fallback if 'ER' is too focused on financial results. Since it is a major, time-sensitive announcement about regulatory progress, it functions similarly to an ER in terms of market impact, but 'RNS' covers general regulatory news best. Given the options, and that it is a formal 'Company Announcement' detailing a regulatory step, RNS is a strong candidate. Let's re-evaluate against ER: ER is for initial announcement of *financial* results. This is a regulatory/clinical update. Therefore, RNS (Regulatory Filings/General Announcement) is the most fitting category for this specific type of material, non-financial, regulatory news update.
2019-12-13 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.